

ORIGINAL ARTICLE

Evaluation of UCA1/miR-138/CDK6 Network in the Patients with Laryngeal Squamous Cell Carcinoma

Laringeal Skuamöz Hücreli Karsinomlu Hastalarda UCA1/miR-138/CDK6 Ağının Değerlendirilmesi

¹Neslihan Cinkara , ¹Çiğdem Yuce Karaman , ²Arzu Tatar , ¹Abdulgani Tatar 

¹Department of Medical Genetics, Faculty of Medicine, Ataturk University, Erzurum, Türkiye

²Department of Otorhinolaryngology, Faculty of Medicine, Ataturk University, Erzurum, Türkiye

Correspondence

Çiğdem Yuce Karaman, Assoc. Prof. Ataturk University, Faculty of Medicine, Department of Medical Genetics Erzurum, Türkiye

E-Mail: cigdem.kahraman@atauni.edu.tr

How to cite ?

Cinkara N, Yuce Karaman C, Tatar A, Tatar A. Evaluation of UCA1/miR-138/CDK6 Network in the Patients with Laryngeal Squamous Cell Carcinoma. Genel Tıp Derg. 2024;34(5):666-70.

ABSTRACT

Objective: Noncoding RNAs (ncRNAs) have the potential to be diagnostic and therapeutic targets, in many cancer types. miRNA \square mRNA ceRNA (competing endogenous RNA) network in cancer has been an interesting topic in the recent research. We aimed to investigate the relationship of The urothelial cancer-associated one gene (UCA1)/miR-138/CDK6 network with laryngeal squamous cell carcinoma (LSCC).

Material and Methods: We studied the samples of adjacent normal tissue from patients diagnosed with LSCC in addition to the samples of malignant tissue. Following the RNA isolation of the samples, UCA1, miR-138, and CDK6 expression analysis was performed using the quantitative real-time PCR (qRT-PCR) method.

Results: Expressions of cancerous tissue samples and adjacent normal tissue samples as controls were compared. CDK6 and UCA1 levels were increased and miR-138 levels were found to be decreased in cancer tissues but not statistically significant.

Conclusion: To the best of our knowledge there is no study to provide an expression profile of the UCA1/CDK6/miR-138 network for LSCC patients. Although we could not obtain statistically significant results, our results were similar with the UCA1, miR-138, and CDK6 axis literature. Further studies with larger patient samples and LSCC cell lines may confirm the function of this axis, which might be a diagnostic and therapeutic target for LSCC.

Keywords: Long non-coding RNA, lncRNA, Laryngeal cancer, miRNA, UCA1, miR138, CDK6

ÖZ

Amaç: Kodlamayan RNA'lar (ncRNA'lar), birçok kanser türünde tanı ve tedavi hedefi olma potansiyeline sahiptir. miRNA – mRNA ceRNA (yarışmalı endojen RNA) ağı son yıllarda üzerinde çalışılan ilginç bir konu olmuştur. Bu çalışmayla UCA1/miR-138/CDK6 ağının laringeal skuamöz hücreli karsinom (LSCC) ile ilişkisini araştırmayı amaçladık.

Gereç ve Yöntem: LSCC tanısı alan hastaların kanserli dokuları ve kontrol olarak da komşu normal doku örneklerinden çalışma yapıldı. Örneklerden RNA izolasyonu yapıldıktan sonra kantitatif gerçek zamanlı PCR (qRT-PCR) yöntemi ile UCA1, miR-138 ve CDK6 ekspresyonları değerlendirildi.

Bulgular: Kanserli ve kontrol doku örneklerinin ekspresyonları karşılaştırıldı. Kanser dokularında, istatistiksel olarak anlamlı olmamakla birlikte CDK6 ve UCA1 ekspresyonunun arttığı, miR-138 ekspresyonunun ise azaldığı belirlendi.

Sonuç: Çalışmamız, bildiğimiz kadarıyla LSCC hastalarında UCA1/CDK6/miR-138 ağı ekspresyon profilinin çalışıldığı ilk çalışmadır. İstatistiksel olarak anlamlı sonuçlar elde edilememiş olmakla birlikte, sonuçlarımız UCA1, miR-138 ve CDK6 ağ çalışmaları literatürüyle benzerdir. Örnek sayısının daha fazla olduğu çalışmalar ve LSCC hücre dizileri ile yapılacak ileri çalışmalar, LSCC için tanı ve tedavi hedefi olabilecek bu yolğun fonksiyonlarını daha da netleştirecektir.

Anahtar Kelimeler: Uzun kodlamayan RNA, lncRNA, Laringeal kanser, miRNA, UCA1, miR138, CDK6

Introduction

Laryngeal cancer is a common type of head and neck cancers and laryngeal squamous cell carcinoma (LSCC) is the most common type of laryngeal cancer with a rate of 90% (1). The long-term prognosis of LSCC patients is considered poor because of frequent metastases and recurrences (2). Therefore, it is essential to identify potential therapeutic targets. Although substantial breakthroughs have been achieved in therapeutic techniques such as surgery, chemotherapy, and radiotherapy, the long-term prognosis of LSCC patients is not adequate due to frequent metastases and recurrences (3). Investigating regulatory mechanisms in LSCC development and progression will contribute to developing effective

therapeutic strategies for LSCC. From this perspective, selecting patients who will benefit from a particular treatment and identifying new biomarkers that predict the clinical outcome will be essential (4). Studies based on DNA sequencing ((5–7), determination of the expression level of RNAs (8,9), and detection of the amounts of translational proteins (10,11) have an important place in the early and differential diagnosis, prognosis and etiopathogenesis of diseases and in developing appropriate treatment strategies.

In the human genome, non-coding RNA genes form functional RNA molecules without coding for proteins and act as regulators in processes that have critical

roles in the cell (12). It is known that non-coding RNAs (ncRNAs) have a role in controlling signaling pathways (13). Among these ncRNAs, long noncoding RNAs (lncRNAs) are the main focus of interest. lncRNAs are classified as non-protein-coding RNA transcripts longer than 200 nucleotides.

In recent years, there has been a greater focus on the role that lncRNAs and miRNAs play in the etiology of cancer. (13). In general, lncRNAs change gene expression levels and play a regulatory role in transcription and post-transcriptional processes, particularly in chromatin remodeling (14). In the current literature, it has been reported that lncRNAs play a role in tumorigenesis and tumour progression and show metastatic properties in various cancer conditions (15).

MiRNAs, are non-coding RNAs which consist of about 19–25 nucleotides and bind to 3' untranslated region (3' UTR) of target genes. Abnormal expression of miRNAs contribute the cancer process. Oncogenic or tumour suppressor miRNAs have been revealed in various cancers (16). According to the ceRNA hypothesis, described by Salmena et al., lncRNAs can act as ceRNAs by competing with miRNAs and preventing them from binding to specific binding sites on mRNA, thereby regulating target genes posttranscriptionally (17). Various studies have shown that ceRNA network plays a vital role in tumour development (18).

In this study, we aimed to investigate the expression levels and interrelationship of the UCA1-miR138-CDK6 (lncRNA-miRNA-mRNA) ceRNA network in the patients with LSCC.

Materials And Methods

Selecting Patients and Keeping Records

This study was planned as a case-control study. Ethics committee approval was obtained from ??? University Faculty of Medicine Research Ethics Committee (approval number: B.30.2.???0.01.00/60).. Thirty patients between the ages 18-70 with LSCC diagnosis were included in the current study. Written informed consent was obtained from all participants. From March 2020 to March 2021, laryngeal tissue samples of individuals with the diagnosis of LSCC in the ENT (Ear-Nose-Throat) clinic were surgically removed (with confirmed frozen biopsy), and thirty pairs of LSCC tissue and matching adjacent normal tissue samples were collected. None of the patients received

chemotherapy, radiotherapy or biotherapy before surgery. Diagnosis of the patients were confirmed by pathological analysis. All samples were frozen in liquid nitrogen within 5 minutes after resection and then stored at -80°C until further use for RNA analysis.

After considering the inclusion and exclusion criteria, UCA1, miR-138, and CDK6 expression analysis was performed after total RNA isolation from tissues or cells, cDNA synthesis, and quantitative real-time polymerase chain reaction (qRT-PCR). Several control genes were included in the study to ensure normalization. Control genes GAPDH for lncRNA, GAPDH for mRNA, and RNU6 for miRNA were selected.

Expression Analysis of RNAs

Bioinformatics tools such as miRcode and TargetScan developed to identify competing triplets associated with lncRNA were used to predict miRNA-lncRNA interactions. MiRNA-mRNA interactions were obtained from two high-quality databases, miRDB and miTarBase. lncRNA-mRNA pairs sharing a miRNA, the UCA1/miR-138/CDK6 network was constructed as a candidate for lncRNA-miRNA-mRNA ceRNA axis.

Analysis of Data

During the PCR reaction, as the amplification process took place, the released fluorescence given by the SYBER Green dye was recorded by the Real-Time PCR, and the Ct values of each sample according to the initial concentration were automatically calculated by the device. Ct values and Ct curve graphs of 30 pairs of samples accepted as patient and control were analyzed and recorded in the Rotor-Gene Software program. lncRNA, mRNA, and miRNA expression changes were calculated by the comparative Ct method known as the $2^{-\Delta\Delta Ct}$ (Livak) method. Fold change = $2^{-\Delta\Delta Ct}$ is the normalized miRNA expression in each test sample divided the normalized miRNA expression in the control sample. Average Ct values for each gene of the groups of patients and controls were calculated. Average ΔCt and $\Delta\Delta Ct$ values were calculated. $\Delta Ct = Ct \text{ Target Gene} - Ct \text{ Reference Gene}$. $\Delta\Delta Ct = \text{Group of the patients } \Delta Ct - \text{Group of the controls } \Delta Ct$. Within the scope of the study, the data were summarized using descriptive statistics. For this purpose, mean values were calculated for RNA expression levels. Student's T-test was used to compare two independent groups in terms of customarily distributed numerical variables. A value of $p < 0.05$ was considered statistically significant.

Results

Expression Analysis Findings

The expression levels of UCA1, CDK6, miR-138 genes were determined in the patient and control groups by normalizing with the GAPDH, GAPDHP61 and RNU6 reference genes. Ct values of 30 pairs of samples accepted as case and control were analyzed (Tab.1)

Table 1. Mean Ct and Δ Ct values detected for UCA1, CDK6, miR-138, GAPDH, GAPDHP61 and RNU6

	Average Ct values		Average Δ Ct values (Ct (target RNA)- Ct (reference RNA))	
	Patient group	Control group	Patient group	Control group
UCA1	26,43	27,06	6,95	7,29
CDK6	22,26	23,56	3,59	4,80
miR-138	20,12	20,87	0,88	-1,95
GAPDHP61	14,98	15,97	0	0
GAPDH	20,11	19,76	0	0
RNU6	19,23	22,00	0	0

UCA1, miR-138, and CDK6 expression levels in LSSC and adjacent normal tissues as controls were examined and fold changes were determined (Tab.2)

Table 2: 'Fold Change' of UCA1, CDK6, miR-138, compared to controls and p values

	Fold Change	p - values
UCA1	1,27	0,35
CDK6	2,32	0,08
miR-138	0,28	0,25

Fold change: $2^{-\Delta\Delta Ct}$ ($\Delta\Delta Ct = \text{Patient Group } \Delta Ct - \text{Control Group } \Delta Ct$)

The fold change of CDK6 was increased 2.32 times in laryngeal cancer compared to control ($p < 0.08$). It was not found to be statistically significant (Figure 1).




Figure 1. Fold change values of patient and control groups.

UCA1 was expressed 1.27 times higher in LSSC tissues compared to controls, but it was not found to be statistically significant. However, a 0.28-fold decrease in miR-138 RNA levels was detected in LSSC tissues compared to controls. The difference in miRNA expression levels between the two groups was not statistically significant. (Figure 1).

Discussion

UCA1, an oncogenic lncRNA, was initially identified in bladder cancer tissues. It has been demonstrated that UCA1 is upregulated and has carcinogenic effects in various cancers (19). In a study by Sun et al., UCA1 was significantly upregulated in most LSSC patients, and it enhanced the ability of LSSC cells to proliferate, migrate, and invade by activating the Wnt/ β -catenin signaling pathway in tumour tissues compared to the adjacent healthy tissues (20). It was found that overexpression of UCA1 in lung cancer increased cancer cells' proliferation, migration, and invasion abilities reversing the tumour suppressor effect of miR-138 and miR-193 in a study on the UCA-1, miR-138, miR-193, and CDK6 axis. In the same study, a negative correlation was shown between miR-138 and miR-193 and UCA1 expressions. These findings supported that UCA1 might control CDK6 expression by targeting miR-138 and miR-193, which are both targets of UCA1 and CDK6 (21). We aimed to study this axis, which has been studied in lung cancer, in LSSC. Although we could not obtain statistically significant results, our results were similar with this data; UCA1 and CDK6 expressions were up regulated while miR-138 was down regulated in the UCA-1, miR-138, and CDK6 axis. In another study on UCA1/miR-185-5p/ HOXA13 axis on LSSC tissues and cell lines, UCA1 expression was upregulated, and UCA1 regulated the proliferation and migration of the cells via the miR-185-5p/HOXA13 axis (22).

MiR-138 is highly conserved among vertebrates and has been shown to play a role in organogenesis (16). Dysfunction of miR-138 has been observed in various tumour types. MiR-138 has been defined as a tumour suppressor in cancers by targeting various oncogenes. In a study by Wang et al., miR-138 was selected as a candidate miRNA in the TRPM2-AS /miR-138/SOX4 axis (23). They found that TRPM2-AS sponged miR-138 to eliminate its repression on SOX4 function in LSSC cells and miR-138 was down regulated (23). It has been shown that miR-138, is down regulated in cancer cells, targets histone methyltransferase EZH2, and reduces the metastasis of cancer cells (24). EZH2 and miR-138 relationship has also been documented in several other forms of cancer such as; clear cell renal cell cancer, nonsmall cell lung cancer, osteosarcoma and glioblastoma (25). In another study, the decrease of miR-138 expression in LSSC cell lines and the suppressive role of miR-138 in LSSC cell proliferation by inhibiting EZH2 expression and the PI3K/AKT pathway

has been reported. As a result, it has been postulated that the miR-138/EZH2 axis may be a promising therapeutic target for LSCC (26). Gao et al. reported that miR-138 was down-regulated in LSCC tissues compared to matched normal laryngeal tissue. ZEB2, the target of miR-138, was conversely up-regulated. They suggested miR-138 as a potential therapeutic target for ZEB2-induced LSCC (27). In our study, miR-138 was found down regulated in LSCC samples in accordance with the literature, but it was not found to be statistically significant.

CDK6 is the main regulator of the G1/S cell cycle transition. CDK6 expression is high in head and neck squamous cell carcinoma and is associated with tumour progression. CDK6 plays critical roles in cell proliferation, cycling, differentiation, and metastasis. CDK6 expression has been shown to be upregulated and functions as an oncogene in LSCC (28). In a study of CDKN2B-AS1/miR-497/CDK6 axis in LSCC, it was reported that the lncRNA; CDKN2B-AS1 targets miR-497/CDK6. They found that CDK6 and CDKN2B-AS1 was up regulated and miR-497 was down regulated in LSCC tissues. With these results, they suggested that CDKN2B-AS1 is a miR-497 sponge in LSCC cells and thus upregulates CDK6 expression (29). In our study, CDK6 expression was increased in LSCC tissues compared to adjacent healthy tissues, in agreement with the previously published reports.

Biomarkers are widely used as powerful tools for patient diagnosis, disease staging and monitoring, and predicting clinical prognosis (28). The potential of ceRNAs as biomarkers is further enhanced by the fact that ncRNAs are found in body fluids such as blood, urine, or in the extracellular vesicles, including exosomes. The ceRNA network have been characterized in various cancers in recent years (14,18). The discovery of these interactions has offered a new perspective on cancer diagnosis, prognosis and therapy. In our study, the UCA1/miR-138/CDK6 axis, one of the ceRNA networks with the potential to be a biomarker in cancer, was studied in LSCC tissues.

The ceRNA network on cancer diagnosis, prognosis and therapy is an intriguing issue. To the best of our knowledge there is no study to provide an expression profile of the UCA1-CDK6-miR-138 ceRNA network for LSCC patients. Although we could not obtain statistically significant results, our results were similar with the UCA-1, miR-138, and CDK6 axis literature. Sample number is a limitation of our study. Further studies with larger patient samples and LSCC cell lines

may confirm the function of this axis, which might be a diagnostic and therapeutic target for LSCC.

Statements and Declarations

Ethics Committee Approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of ??? University (B.30.2.???0.01.00/60). Written informed consent was obtained from all participants.

Conflicts of interest

The authors declare no conflict of interest.

Financial Disclosure

This study was supported by a grant from ??? University BAP coordinatory unit (project number.TTU- 2021-9277).

Authors' contributions

Concept and design: NC, CYK, AT, literature search: NC, CYK, data acquisition and analysis: NC, CYK, AT, manuscript preparation: NC, CYK, manuscript editing and manuscript review: NC, CYK, AT. All authors contributed to manuscript drafting and approved the final version.

References

- Kong X, Qi J, Yan Y, et al. Comprehensive analysis of differentially expressed profiles of lncRNAs, mRNAs, and miRNAs in laryngeal squamous cell carcinoma in order to construct a ceRNA network and identify potential biomarkers. *J Cell Biochem.* 2019;120(10):17963–74.
- Zhang Q, Wang H, Zhao Q, et al. Evaluation of Risk Factors for Laryngeal Squamous Cell Carcinoma: A Single-Center Retrospective Study. *Front Oncol.* 2021;11(Febuary).
- Li H, Wang FL, Li W, et al. Aberrant expressed long non-coding RNAs in laryngeal squamous-cell carcinoma. *Am J Otolaryngol - Head Neck Med Surg.* 2019;40(5):615–25.
- Liu H, Sun Y, Tian H, et al. Characterization of long non-coding RNA and messenger RNA profiles in laryngeal cancer by weighted gene co-expression network analysis. *Aging (Albany NY).* 2019;11(22):10074–99.
- Aslantas M, Kilicaslan O, Eröz R, et al.. The Evaluation of the Genetic Variation Types of the Uridine Diphosphate Glucuronosyl Transferase 1A1 Gene by Next-Generation Sequencing and Their Effects on Bilirubin Levels in Obese Children. *Genet Test Mol Biomarkers.* 2024;28(7).
- Doğan M, Eröz R, Tecelioğlu M, et al.. Clinical and Molecular Findings in a Turkish Family Who Had a (c.869- 1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis. *Curr Alzheimer Res.* 2022;19(3):223–35.
- Arslanoğlu I, Eröz R, Yavuzylmaz F, et al.. Variations In Monogenic Diabetes And Diabetes Susceptibility Genes In Pediatric Cases: Single Center Experience. *Acta Endocrinol.* 2023;19(4):512–22.
- Acat M, Yıldız Gülhan P, Eröz R, et al.. Evaluation of both expression and serum protein levels of caspase-8 and mitogen-activated

- protein kinase 1 genes in patients with different severities of COVID-19 infection. *Mol Biol Rep* [Internet]. 2023;50(4):3241–8. Available from: <https://doi.org/10.1007/s11033-023-08244-4>
9. Tuşat M, Eroz R, Böllükbaşı F, et al. Evaluation of the protective and therapeutic effects of extra virgin olive oil rich in phenol in experimental model of neonatal necrotizing enterocolitis by clinical disease score, inflammation, apoptosis, and oxidative stress markers. *Pediatr Surg Int* [Internet]. 2024;40(1). Available from: <https://doi.org/10.1007/s00383-024-05669-1>
10. Karagun E, Eroz R. Argyrophilic nucleolar organizing regions in patients with Xeroderma Pigmentosum Group E. *Exp Dermatol*. 2021;30(3):416–7.
11. Damar İH, Eroz R. Argyrophilic Nucleolar Organizer Regions as New Biomarkers in ST-Elevation Myocardial Infarction. *J Cardiovasc Dev Dis*. 2022;9(2).
12. Shen Z, Li Q, Deng H, Lu D, et al. Long non-coding RNA profiling in laryngeal squamous cell carcinoma and its clinical significance: Potential biomarkers for LSCC. *PLoS One*. 2014;9(9):1–9.
13. Cossu AM, Mosca L, Zappavigna S, et al. Long non-coding RNAs as important biomarkers in laryngeal cancer and other head and neck tumours. *Int J Mol Sci*. 2019;20(14).
14. Shi Y, Yang D, Qin Y. Identifying prognostic lncRNAs based on a ceRNA regulatory network in laryngeal squamous cell carcinoma. *BMC Cancer*. 2021;21(1):1–15.
15. Lorenzi L, Avila Cobos F, Decock A, et al. Long noncoding RNA expression profiling in cancer: Challenges and opportunities. *Genes Chromosom Cancer*. 2019;58(4):191–9.
16. Yeh M, Oh CS, Yoo JY, et al. Pivotal role of microRNA-138 in human cancers. *Am J Cancer Res* [Internet]. 2019;9(6):1118–26. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/31285946> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6610051>
17. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: The rosetta stone of a hidden RNA language? *Cell* [Internet]. 2011;146(3):353–8. Available from: <http://dx.doi.org/10.1016/j.cell.2011.07.014>
18. Zhang Y, Xu Y, Feng L, et al. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. *Oncotarget*. 2016;7(39):64148–67.
19. Xuan W, Yu H, Zhang X, et al. Crosstalk between the lncRNA UCA1 and microRNAs in cancer. *FEBS Lett*. 2019;593(15):1901–14.
20. Sun S, Gong C, Yuan K. lncRNA UCA1 promotes cell proliferation, invasion and migration of laryngeal squamous cell carcinoma cells by activating Wnt/ β -catenin signaling pathway. *Exp Ther Med*. 2018;1182–9.
21. Xun G, Ma M, Li B, et al. miR-138 and miR-193 target long non-coding RNA UCA1 to inhibit cell proliferation, migration, and invasion of lung cancer. *Thorac Cancer*. 2020;11(9):2681–9.
22. Sun YD, Liu Q, Yang HX, et al. Long non-coding RNA UCA1 mediates proliferation and metastasis of laryngeal squamous cell carcinoma cells via regulating miR-185-5p/HOXA13 axis. *Eur Rev Med Pharmacol Sci*. 2021;25(3):1366–78.
23. Wang N, Wang L, Pan X. Long non-coding rna trpm2-as promotes cell migration and invasion by serving as a ceRNA of miR-138 and inducing sox4-mediated emt in laryngeal squamous cell carcinoma. *Cancer Manag Res*. 2020;12:7805–12.
24. Qiu S, Huang D, Yin D, et al. Suppression of tumorigenicity by MicroRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. *Biochim Biophys Acta - Mol Basis Dis* [Internet]. 2013;1832(10):1697–707. Available from: <http://dx.doi.org/10.1016/j.bbdis.2013.05.015>
25. Zhu Z, Tang J, Wang J, et al. MIR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells. *PLoS One*. 2016;11(3):1–12.
26. Si F, Sun J, Wang C. MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting EZH2 and PI3K/AKT signaling. *Exp Ther Med*. 2017;14(3):1967–74.
27. Gao S, Wang J, Xie J, et al. Role of miR-138 in the regulation of larynx carcinoma cell metastases. *Tumor Biol* [Internet]. 2016;37(12):15601–6. Available from: <http://dx.doi.org/10.1007/s13277-015-4244-y>
28. Poomsawat S, Sanguansin S, Punyasingh J, et al. Expression of cdk6 in head and neck squamous cell carcinoma. *Clin Oral Investig*. 2016;20(1):57–63.
29. Cui X, Yu T, Shang J, et al. Long non-coding RNA CDKN2B-AS1 facilitates laryngeal squamous cell cancer through regulating miR-497/CDK6 pathway. *Onco Targets Ther*. 2019;12:8853–62.